aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

aTyr Pharma (NASDAQ: ATYR), a clinical-stage biotech company, has granted stock options to two new employees as part of their inducement compensation package. The options allow the purchase of 36,200 shares of common stock at $3.00 per share, matching the closing price on May 15, 2025. These grants, made under the aTyr Pharma 2022 Inducement Plan, follow Nasdaq Listing Rule 5635(c)(4).

The options vest over four years, with 25% vesting after one year and the remaining 75% vesting monthly over three years, contingent on continued employment. aTyr focuses on developing first-in-class medicines from its tRNA synthetase platform, with their lead candidate efzofitimod targeting interstitial lung disease treatment.

News Market Reaction

+5.20%

1 alert

+5.20% News Effect

On the day this news was published, ATYR gained 5.20%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, May 16, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr’s Board of Directors has granted two employees nonstatutory stock options to purchase an aggregate of 36,200 shares of aTyr’s common stock, each with an exercise price of $3.00 per share, which is equal to the closing price of aTyr’s common stock on the Nasdaq Capital Market on May 15, 2025, the effective date of the grants. These stock awards were granted as an inducement material to the new employees entering into employment with aTyr in accordance with Nasdaq Listing Rule 5635(c)(4) and were made pursuant to the aTyr Pharma, Inc. 2022 Inducement Plan.

Each option vests over a period of four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the remaining 75% vesting in equal monthly installments over three years, subject to the applicable employee’s continued employment with aTyr through each vesting date. The options are subject to the terms and conditions of the aTyr Pharma, Inc. 2022 Inducement Plan and the terms and conditions of an award agreement covering the grant.

About aTyr

aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.

Contact:
Ashlee Dunston
Sr. Director, Investor Relations and Public Affairs
adunston@atyrpharma.com 

FAQ

What stock options did aTyr Pharma (ATYR) grant to new employees in May 2025?

aTyr Pharma granted two employees nonstatutory stock options to purchase 36,200 shares at $3.00 per share, with a four-year vesting schedule starting May 15, 2025.

What is the vesting schedule for aTyr Pharma's (ATYR) May 2025 employee stock options?

The options vest over 4 years, with 25% vesting after the first year and the remaining 75% vesting in equal monthly installments over three years, subject to continued employment.

What is aTyr Pharma's (ATYR) main business focus?

aTyr is a clinical stage biotech company developing first-in-class medicines from its tRNA synthetase platform, focusing on treatments for fibrosis and inflammation.

What is efzofitimod and what is it being developed for by aTyr Pharma (ATYR)?

Efzofitimod is aTyr's lead therapeutic candidate, a first-in-class biologic immunomodulator being developed for the treatment of interstitial lung disease.